List of works - Barbro K Linderholm

A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns

scientific article published on 10 June 2020

A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

scientific article published on 01 January 2011

Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen

scientific article published on 05 April 2006

Alterations of the immunoglobulin heavy chain locus in progressive B-cell lymphomas.

scientific article published in January 1998

An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.

scientific article published on October 2008

Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.

scientific article published on 20 August 2013

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer

scientific article published on 07 January 2014

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer

Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis.

scientific article published on 19 August 2013

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy

scientific article published on 16 January 2013

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

scientific article published on 18 November 2011

Molecular profiling of male breast cancer - lost in translation?

scientific article published on 16 May 2014

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment

scientific article published on 01 January 2004

Person and Family Centeredness in Ethiopian Cancer Care: Proposal for a Project for Improving Communication, Ethics, Decision Making, and Health

scientific article published on 19 May 2020

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.

scientific article published on 21 April 2010

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

scientific article published on January 2013

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.

scientific article

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

scientific article published on 23 June 2009

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

scientific article published in 2021

Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers

scientific article published on 01 November 2004

Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.

scientific article published on 27 May 2008

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer.